|
|
|
|
|
 |
| Welcome
to Oncology Europe
03.07.2009 |
 |
This
website has been created to help inform and support physicians treating cancer
patients. It includes publications, conference reports, new data and concise
information
in the field of oncology.
|
What's new on Oncology Europe
|
|
Congress reminder
|
Nov 14-15, 2008
ESH - EHA Tutorial on Haematological Malignancies
Dublin, Ireland
|
|
Read more... |
|
Link of the week
|
Site
of the
European Organisation
for Research and Treatment of Cancer
|
|
Read more...
|
|
  | High level of agreement among surgeons on resectability of liver metastases in patients with WT KRAS mCRC tumours receiving cetuximab
03.07.2009
Patients with metastatic colorectal cancer (mCRC) whose tumours express the wild type KRAS gene respond well to treatment with the EGFR-targeting therapy Erbitux (cetuximab). This often gives those with initially unresectable metastases confined to the liver, the chance of undergoing resection, and potentially experiencing what amounts to a ‘cure’.
Read more...
 |
| Recommendations on diagnostics, therapy and aftercare 2009
02.07.2009
Treatment of the HCC depends both on tumor factors as on factors related to the underlying hepatic disease. Curative treatment options such as resection, liver transplantation or radiofrequency ablation can only be used for a minority of the patients.
Read more...
|
| New approval in the adjuvant setting
01.07.2009
Imatinib has now also been approved in the adjuvant setting for the treatment of adults with significant risk of recidivation after resection of c-Kit (CD117)-positive GIST. Prof.
Read more...
|
| St. Gallen: A vast majority for upfront therapy
30.06.2009
Aromatase-inhibitors are without doubt superior to tamoxifen in postmenopausal women with hormone-sensitive early breast cancer. Updates presented at St. Gallen confirm the clinical benefit of anastrozole – including substantial risk reductions and a benefit that is maintained for many years after the therapy has been terminated.
Read more...
|
| Interesting expert votes in St. Gallen
29.06.2009
At the center of interest at this year’s St. Gallen Consensus Meeting (March 2009) was the consensus panel discussion with a gremium of 43 experts from 17 countries debating various clinical aspects of the therapy of early breast cancer. Prof. Dr. Michael Gnant, University Clinic for Surgery, Medical University Vienna, describes his impression of the voting in this interview with Jatros Hämatologe & Onkologie.
Read more...
|
| Treatment of Chronic Myelogenous Leukaemia with Nilotinib
26.06.2009
Chronic Myelogenous Leukemia (CML) is a relatively rare hematologic malignancy. Before any efficacious treatment became available, the median survival was around 4 to 5 years. Allogeneic bone marrow transplantation (BMT) is the only form of treatment able to cure the disease permanently.
Read more...
|
|
Next >
Service-Center: Power Point Presentations >
onco-europe-portal: New Stuff >
Oncological-Societies Europe >
All articles > 
Archive > |
|
|
|
|
|
|
|